AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01750229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5882 Hz
Description: Frequency Setting - 5882 Hz
Study NCT01092546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
Study NCT02346721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily
Study NCT00408200 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propafenone; flecainide; sotalol; dofetilide
Description: Above drugs prescribed per established guidelines for treatment of AF
Study NCT00408200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency catheter ablation
Description: A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
Study NCT00892476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Supplementation
Description: Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp
Study NCT00892476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
Study NCT02229669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal incisions
Description: Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
Study NCT02229669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oblique incisions
Description: Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
Study NCT01855061 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity.
Study NCT01855061 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
Study NCT01855061 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacokinetics
Description: Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
Study NCT01855061 — intervention group
Intervention type: PROCEDURE
Intervention: Midazolam clearance test
Description: Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
Study NCT02922647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: suprapubic catheterization
Description: Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
Study NCT02922647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheterization
Description: Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
Study NCT02342236 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cemented or cementless type of hip prothesis
Study NCT04455815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
Study NCT02747498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure with circumferential pulmonary vein isolation
Description: We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
Study NCT02747498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure with linear ablation in addiction to pulmonary vein isolation
Description: We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
Study NCT04909281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-sampling HPV
Description: In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
Study NCT00124514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate
Description: IM injection given monthly
Study NCT00124514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: IM injection given monthly
Study NCT00124514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.9% normal saline IM injection
Study NCT01042106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-8658
Description: Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
Study NCT01042106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5, 10, 20, 40 mg orally once daily
Study NCT00196313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Description: 1 tablet daily by mouth
Study NCT00196313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet daily by mouth
Study NCT01167413 — intervention group
Intervention type: DEVICE
Intervention: Evaluation by manual Dolorimeter
Description: Patients will be examined by a manual Dolorimeter
Study NCT01167413 — intervention group
Intervention type: OTHER
Intervention: SIJ imaging
Description: Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
Study NCT02445898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
Study NCT02445898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study NCT00645996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (L.acidophilus and B.lactis)
Description: 2.1 X 109 L.acidophilus and B.lactis
Study NCT00645996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornflor
Description: Cornflour 2 gram daily
Study NCT02145377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E8
Description: Oral dose of PXVX0200 10E8
Study NCT02145377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E9
Description: Oral dose of PXVX0200 10E9
Study NCT02145377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose of sodium bicarbonate buffer
Study NCT02145377 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: Licensed comparator
Study NCT00905801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CT Perfusion
Description: Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
Study NCT02067481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
Study NCT01941186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
Study NCT02386540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
Study NCT02670096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
Study NCT01915589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
Study NCT02560558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
Study NCT02560558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
Study NCT02245217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan to assess treatment efficacy
Study NCT04926389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks
Description: one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
Study NCT04926389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-level laser therapy applied every 3 weeks
Description: one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
Study NCT04366817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological assessment
Description: psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
Study NCT03849508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Study NCT03849508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Study NCT02999672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
Study NCT03854097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intermittent Negative Pressure (INP)
Description: Application of -40mmHg negative pressure on the lower limb
Study NCT03854097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intermittent Negative Pressure (INP)
Description: Application of -10mmHg negative pressure on the lower limb
Study NCT00787358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZT-031
Description: 80 ul subcutaneous injection per day
Study NCT00787358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 80 ul daily subcutaneous injection of vehicle only
Study NCT04640220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Description: Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
Study NCT03470298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
Study NCT00132704 — intervention group
Intervention type: RADIATION
Intervention: Ionizing radiation (IR) therapy
Description: Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
Study NCT00132704 — intervention group
Intervention type: RADIATION
Intervention: Ionizing radiation (IR)
Description: Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
Study NCT03562377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
Study NCT03562377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study NCT03562377 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tdap vaccine
Description: Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
Study NCT03562377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Description: Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
Study NCT03562377 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Meningococcal vaccine
Description: This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
Study NCT03562377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine
Description: This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
Study NCT04495920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-S-100
Description: Alcohol and choline geranate
Study NCT02633709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
Study NCT02633709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 1 of the study matching oral placebo will be administered once on Day 1.
Study NCT02633709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
Study NCT03135964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filler dressing of NPWT
Description: a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
Study NCT02542319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg
Study NCT02542319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01775618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
Study NCT01775618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
Study NCT01775618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug